Patients with lung cancer having specific genetic alterations in ALK (Anaplastic Lymphoma Kinase) gene were able to live longer and the spread of the cancer to the brain was prevented when the patients were treated lorlatinib (Lorbrena). Lorlatinib is an anticancer drug which acts by inhibiting Anaplastic Lymphoma Kinase (ALK).
The study was published in iNew England Journal Medicine./i
87% of all cases of lung cancer are Non-small-cell lung cancer (NSCLC) out of which 5% cases are of ALK-positive....
Patients with lung cancer having specific genetic alterations in ALK (Anaplastic Lymphoma Kinase) gene were able to live longer and the spread of the cancer to the brain was prevented when the patients were treated lorlatinib (Lorbrena). Lorlatinib is an anticancer drug which acts by inhibiting Anaplastic Lymphoma Kinase (ALK).
The study was published in iNew England Journal Medicine./i
87% of all cases of lung cancer are Non-small-cell lung cancer (NSCLC) out of which 5% cases are of ALK-positive....